|1.||Gibb, D M: 1 article (11/2010)|
|2.||Chintu, C: 1 article (11/2010)|
|3.||Thomason, M: 1 article (11/2010)|
|4.||Chijoka, C: 1 article (11/2010)|
|5.||Kabamba, D: 1 article (11/2010)|
|6.||Kankasa, C: 1 article (11/2010)|
|7.||Walker, A S: 1 article (11/2010)|
|8.||Kityo, C: 1 article (11/2010)|
|9.||Cook, A: 1 article (11/2010)|
|10.||Ferrier, A: 1 article (11/2010)|
|1.||HIV Infections (HIV Infection)
|2.||Body Weight (Weight, Body)
01/01/2010 - "Patients (8-<12 kg, 18-<22 kg or 28-<32 kg body weight) taking Triomune 40 were recruited and randomized to receive GT twice daily (one-quarter, one-half or three-quarter tablets using Malawi treatment guidelines), GL twice daily (in the equivalent dose of GT) or TL twice daily (dosed using weight and age from US Department of Health and Human Services paediatric treatment guidelines). "
05/01/2007 - "Using a fixed-dose combination of stavudine+lamivudine+nevirapine ('Triomune') as the first-line regimen, split tablets are given to children with doses according to body weight. "
12/01/2009 - "To determine the relationship between nutritional status and nevirapine exposure by comparing the pharmacokinetics of nevirapine in HIV-infected children of different ages with and without malnutrition receiving divided tablets of Triomune 30 (stavudine + lamivudine + nevirapine) in accordance with Malawi National Guidelines. "